Welcome to our dedicated page for Merck & Co SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-trial results buried in Merck鈥檚 300-page 10-K can dictate the future of therapies like Keytruda, yet those details are easy to miss. Add patent-expiration tables, FDA correspondence, and worldwide vaccine sales data and you have one of the most complex disclosure packages in the market. That鈥檚 why professionals searching for Merck & Co. SEC filings explained simply come here first.
Stock Titan鈥檚 AI reads every Merck & Co. annual report 10-K simplified, Merck & Co. quarterly earnings report 10-Q filing, and Merck & Co. 8-K material events explained the moment they hit EDGAR. Our technology pinpoints where management discusses pipeline milestones, litigation reserves, or emerging biosimilar risks so you can act quickly instead of parsing footnotes.
- Get instant alerts on Merck & Co. Form 4 insider transactions real-time and spot trading patterns before key data releases.
- See concise takeaways from every Merck & Co. proxy statement executive compensation to understand how R&D targets drive bonuses.
- Dive into patent expiry schedules and regional vaccine sales in seconds with AI-generated tables.
Whether you鈥檙e monitoring Merck & Co. insider trading Form 4 transactions, comparing quarter-over-quarter oncology revenue, or simply understanding Merck & Co. SEC documents with AI, our platform delivers. Each document arrives with a plain-language summary, key-metric extraction, and cross-linking to prior periods for seamless Merck & Co. earnings report filing analysis. No more hunting through exhibits鈥攋ust clean insights updated in real time.
Merck & Co. (MRK) Form 4 鈥� 5 Aug 2025: EVP & Chief Information & Digital Officer David M. Williams reported the vesting of 17,119 restricted stock units (RSUs) on 4 Aug 2025 (code M). The shares were issued at the market price of $79.29 and immediately reduced by 8,432 shares (code F) that the issuer withheld to cover tax obligations. Net increase to Williams鈥檚 direct ownership is +8,687 shares, bringing his total direct holding to 33,013.467 shares. The related RSU grant is now fully settled; no derivative securities remain.
The footnote clarifies a prior filing error: the RSUs were previously disclosed as vesting in three annual tranches, but actually vested in one installment on 4 Aug 2025. No other transactions, sales to the open market, or new option grants were disclosed.
Merck & Co., Inc. (NYSE: MRK) filed an 8-K disclosing two key items. Item 2.02 furnishes, but does not file, the company鈥檚 Q2-25 earnings press release (Ex. 99.1) and related supplemental information (Ex. 99.2); specific financial figures are not included in this filing.
Item 2.05 launches a new 鈥�2025 Restructuring Program.鈥� Approved 25 Jul 2025, the plan targets sales, administrative and R&D head-count reductions, a smaller real-estate footprint and continued manufacturing network optimization. Merck expects:
- Total pretax charges: 鈮� $3.0 billion; ~60 % cash (severance & contract terminations) and the balance non-cash (accelerated depreciation).
- Major actions largely finished by end-2027; manufacturing actions substantially done by end-2029.
- Annual cost savings: 鈮� $1.7 billion realized by end-2027.
Merck & Co., Inc. (MRK) 鈥� Form 4 insider transaction filing
Director Christine E. Seidman reported two minor changes to her beneficial ownership as of 30 June 2025:
- Non-derivative securities: a disposition of 100 shares of Merck common stock (transaction code and price not disclosed). Her post-transaction direct holding is shown as 100 shares.
- Derivative securities: acquisition of 102.6402 phantom stock units at a reference price of $79.16. Phantom stock is settled 1-for-1 in cash after the director leaves the board under Merck鈥檚 Deferred Payment of Directors鈥� Compensation Plan. Total phantom units after the transaction stand at 18,495.8789.
No other equity awards, options, or material transactions were reported. Given Merck鈥檚 multibillion-dollar market capitalization, the size of these trades is immaterial and should not affect the company鈥檚 valuation or governance structure.
FAQ
What is the current stock price of Merck & Co (MRK)?
What is the market cap of Merck & Co (MRK)?
